No Data
No Data
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy
Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...
Longest Follow-Up Data Reported for Kite's Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences